UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K/A

(Amendment No. 1)

CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 18, 2021

PIERIS PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

	Nevada (State or other jurisdiction of	001-37471 (Commission		30-0784346 (IRS Employer	
	Incorporation)	File Number)		Identification No.)	
		255 State Street, 9th Floor	02109		
		Boston, MA			
		(Address of principal executive offices)	(Zip Code)		
		Registrant's telephone number, including	g area code: 857-24	6-8998	
N/A					
		(Former name or former address, if ch	anged since last rep	port.)	
	the appropriate box below if the Fong provisions:	orm 8-K filing is intended to simultaneously	satisfy the filing ob	ligation of the registrant under any of the	
	☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)				
	□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)				
	□ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))				
	□ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))				
Securitie	es registered pursuant to Section 12(b)	of the Act:			
	Title of each class	Trading Symbo	l(s)	Name of each exchange on which registered	
	Common Stock, \$0.001 par value per	share PIRS		The Nasdaq Capital Market	
	e by check mark whether the regist 2b-2 of the Securities Exchange Ac		ned in Rule 405 of t	he Securities Act of 1933 (17 CFR §230.405) or	
Emergi	ng Growth Company \square				
		by check mark if the registrant has elected n provided pursuant to Section 13(a) of the Ex		ed transition period for complying with any new	

EXPLANATORY NOTE

The sole purpose of this Form 8-K/A is to amend the Form 8-K, filed by Pieris Pharmaceuticals, Inc. with the Securities and Exchange Commission on November 18, 2021, to add Inline eXtensible Business Reporting Language ("XBRL") tagging to the cover page and to furnish Exhibit relating to the same. No other changes have been made.				

Item 7.01 Regulation FD Disclosure.

Attached hereto as Exhibit 99.1 and incorporated by reference herein is the November 2021 Investor Presentation of Pieris Pharmaceuticals, Inc.

The information set forth under this "Item 7.01. Regulation FD Disclosure," including Exhibit 99.1 attached hereto, shall not be deemed "filed" for any purpose, and shall not be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, regardless of any general incorporation language in any such filing except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits.

99.1 <u>Investor Presentation, Dated November 2021</u>.*

104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

* Previously filed

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PIERIS PHARMACEUTICALS, INC.

Dated: January 14, 2022 /s/ Tom Bures

Tom Bures

Chief Financial Officer